NeOnc Technologies Holdings is trading 24.52% up now at $4.36 as investors position ahead of the August 12, 2026, presentation of topline Phase 2a NEO100 results.
- Fully enrolled, the trial evaluates intranasal NEO100 in recurrent or progressive IDH1-mutant high-grade glioma.
- Efficacy, safety and regulatory updates are expected; August 10 earnings highlighted the catalyst despite a wider second-quarter loss.
- The move appears company-specific and catalyst-driven; trading activity is elevated versus flat $3.50 closes, though reliable live volume was unavailable.